Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Laura A. Huppert, Özge Gümüşay, Damé Idossa, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 5, pp. 480-515
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Molecular classification of hormone receptor-positive HER2-negative breast cancer
Xi Jin, Yi-Fan Zhou, Ding Ma, et al.
Nature Genetics (2023) Vol. 55, Iss. 10, pp. 1696-1708
Closed Access | Times Cited: 46
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Jing Wang, Baizhou Li, Meng Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
Rohan Kalyan Rej, Joyeeta Roy, Srinivasa Rao Allu
Cancers (2024) Vol. 16, Iss. 3, pp. 552-552
Open Access | Times Cited: 19
Green synthesis of zinc oxide nanoparticles using Rhus coriaria extract and their anticancer activity against triple-negative breast cancer cells
Youssef Mongy, Thanaa I. Shalaby
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Erika Hamilton, X. Cynthia, Michelino De Laurentiis, et al.
Future Oncology (2024) Vol. 20, Iss. 32, pp. 2447-2455
Open Access | Times Cited: 16
Breast cancer: pathogenesis and treatments
Xin Xiong, Lewei Zheng, Yu‐Qiang Ding, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Platinum(IV) Complexes as Inhibitors of STAT3 and Regulators of the Tumor Microenvironment To Control Breast Cancer
Linxiang Cai, Ying Wang, Hanhua Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 11351-11364
Closed Access | Times Cited: 24
Hyaluronic acid-conjugated methotrexate and 5-fluorouracil for targeted drug delivery
Wanfei Shao, Yanfang Yang, Weidong Shen, et al.
International Journal of Biological Macromolecules (2024) Vol. 273, pp. 132671-132671
Closed Access | Times Cited: 10
Edaravone: A Novel Possible Drug for Cancer Treatment?
Elisa Duranti, Nicoletta Cordani, Chiara Villa
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1633-1633
Open Access | Times Cited: 8
The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer
Samarth Kansara, Agrata Singh, Abhishesh Kumar Badal, et al.
Seminars in Cancer Biology (2023) Vol. 95, pp. 1-12
Closed Access | Times Cited: 17
M2 macrophages promote PD-L1 expression in triple-negative breast cancer via secreting CXCL1
Lifen Zhang, Shanzhi Gu, Lu Wang, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155458-155458
Open Access | Times Cited: 7
CDK7 in breast cancer: mechanisms of action and therapeutic potential
Ying Gong, Huiping Li
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy
Zhouyun Chen, Xiaoxiao Wang, Na Zhao, et al.
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 11, pp. 1623-1642
Closed Access | Times Cited: 13
A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
Hanqiao Shao, Mingye Zhao, Ai‐Jia Guan, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer
Fei Qu, Rongrong Lu, Qian Liu, et al.
Cancer (2024) Vol. 130, Iss. S8, pp. 1392-1402
Closed Access | Times Cited: 5
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 5
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation
Manqi Hua, Fei Xiong, Shan Chong, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102827-102827
Closed Access | Times Cited: 5
Phase I clinical trial to assess safety and efficacy of Oraxol, a novel oral paclitaxel chemotherapy agent, in patients with previously treated metastatic breast cancer
Yunfang Yu, Ying Wang, Luhui Mao, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Research Progress of the Prevention and Treatment of Metabolic Associated Fatty Liver Disease as a Complication Disease of Endocrine Therapy for Breast Cancer
胜鹏 覃
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 581-590
Closed Access
Metastasiertes hormonrezeptorpositives Mammakarzinom – die Qual der Wahl
Marion van Mackelenbergh, Michael Friedrich, Nicolai Maass
Die Gynäkologie (2025)
Closed Access
An oral bioactive chitosan-decorated doxorubicin nanoparticles/bacteria bioconjugates enhance chemotherapy efficacy in an in-situ breast cancer model
Jian‐Mei Li, Qian Wen, Jie Dai, et al.
International Journal of Biological Macromolecules (2024) Vol. 267, pp. 131428-131428
Closed Access | Times Cited: 4
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1494-1510
Open Access | Times Cited: 4
Machine learning Nomogram for Predicting endometrial lesions after tamoxifen therapy in breast Cancer patients
Cao Shaoshan, Niannian Chen, Ying Ma
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2− breast cancer
Hang Zhang, Fan Yang, Y Xu, et al.
Cell Reports Medicine (2025), pp. 101924-101924
Open Access
Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
Lina Zhang, Yueping Liu, Chao Yang, et al.
Breast Cancer Research (2025) Vol. 27, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top